BNP Paribas Asset Management
LEGN icon

BNP Paribas Asset Management’s Legend Biotech LEGN Stock Holding History

BNP Paribas Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$725K Buy
25,098
+2,953
+13% +$79.7K ﹤0.01% 1255
2026
Q1 		$401K Sell
22,145
-2,279
-9% -$43.4K ﹤0.01% 1275
2025
Q4 		$532K Buy
+24,424
New +$700K ﹤0.01% 1244
2025
Q3 		– Sell
-14,043
Closed -$498K – 1981
2025
Q2 		$498K Sell
14,043
-349
-2% -$11.3K ﹤0.01% 799
2025
Q1 		$488K Buy
14,392
+918
+7% +$32.9K ﹤0.01% 803
2024
Q4 		$438K Buy
13,474
+5,459
+68% +$226K ﹤0.01% 842
2024
Q3 		$391K Buy
8,015
+1,451
+22% +$77.3K ﹤0.01% 842
2024
Q2 		$291K Buy
6,564
+2,947
+81% +$136K ﹤0.01% 927
2024
Q1 		$203K Buy
+3,617
New +$218K ﹤0.01% 871

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

BNP Paribas Asset Management's LEGN Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Legend Biotech (LEGN) stake by 13% in Q2 2026, buying an estimated $79.7K and bringing the position to 25,098 shares worth $725K. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

BNP Paribas Asset Management first reported a position in LEGN in Q1 2024 and has held it in 9 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • BNP Paribas Asset Management held 25,098 shares of Legend Biotech worth $725K as of Q2 2026.
  • BNP Paribas Asset Management bought 2,953 Legend Biotech shares in Q2 2026, an estimated $79.7K.
  • Legend Biotech made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1255 holding.
  • BNP Paribas Asset Management first reported a position in Legend Biotech in Q1 2024 and has held it in 9 quarters since.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.